These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

800 related items for PubMed ID: 26916397

  • 1. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS, Saad A, Al-Suwaidi J, Al-Marridi WZ, Elkhalifa DH, Mohamed AA, Mahfoud ZR.
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [Abstract] [Full Text] [Related]

  • 2. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY, Cooke CE, Robertson TA.
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S, Jones PG, Maddox TM, Bradley SM, Stolker JM, Arnold SV, Parashar S, Peterson P, Bhatt DL, Spertus J, Ho PM.
    Heart; 2015 May 15; 101(10):800-7. PubMed ID: 25801001
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Yahia DH, Pereg D, Lishner M, Elis A.
    Harefuah; 2015 May 15; 154(5):299-302, 339-40. PubMed ID: 26168639
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
    Welker J, Auer R, Gencer B, Muller O, Cornuz J, Matter CM, Mach F, Windecker S, Rodondi N, Nanchen D.
    Swiss Med Wkly; 2016 May 15; 146():w14275. PubMed ID: 26859223
    [Abstract] [Full Text] [Related]

  • 9. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
    Di Martino M, Alagna M, Lallo A, Gilmore KJ, Francesconi P, Profili F, Scondotto S, Fantaci G, Trifirò G, Isgrò V, Davoli M, Fusco D.
    BMC Cardiovasc Disord; 2021 Apr 14; 21(1):180. PubMed ID: 33853534
    [Abstract] [Full Text] [Related]

  • 10. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
    Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O.
    J Clin Pharm Ther; 2013 Apr 14; 38(2):97-100. PubMed ID: 23441979
    [Abstract] [Full Text] [Related]

  • 11. Association between the use of 4 recommended drug categories and patient perceptions of health status following an ACS event.
    Erickson SV, Rangarajan K, Kline-Rogers EM, Smith DE, Eagle KA.
    J Manag Care Pharm; 2009 Sep 14; 15(7):533-42. PubMed ID: 19739876
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR, Koshman SL, Norris CM, Ross DB, Pearson GJ.
    Pharmacotherapy; 2014 May 14; 34(5):464-72. PubMed ID: 24877186
    [Abstract] [Full Text] [Related]

  • 13. Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors.
    Gunnell AS, Hung J, Knuiman MW, Nedkoff L, Gillies M, Geelhoed E, Hobbs MS, Katzenellenbogen JM, Rankin JM, Ortiz M, Briffa TG, Sanfilippo FM.
    Cardiovasc Ther; 2016 Dec 14; 34(6):423-430. PubMed ID: 27489053
    [Abstract] [Full Text] [Related]

  • 14. Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice.
    Kassab YW, Hassan Y, Aziz NA, Akram H, Ismail O.
    J Eval Clin Pract; 2013 Aug 14; 19(4):658-63. PubMed ID: 22845427
    [Abstract] [Full Text] [Related]

  • 15. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B, Lesosky M, Ntsekhe M.
    S Afr Med J; 2014 Jun 17; 104(7):483-7. PubMed ID: 25214049
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcome of acute coronary syndrome patients admitted to Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia; A retrospective cross-sectional study.
    Desta DM, Nedi T, Hailu A, Atey TM, Tsadik AG, Asgedom SW, Kasahun GG, Ayalew E.
    PLoS One; 2020 Jun 17; 15(2):e0228953. PubMed ID: 32053702
    [Abstract] [Full Text] [Related]

  • 17. Guideline-Based Medications for Older Adults Discharged after Percutaneous Coronary Intervention in a Suburban City of Japan: A Cohort Study Using Claims Data.
    Shimada K, Hamada S, Sawano M, Yamamoto H, Yoshie S, Iijima K, Miyata H.
    Tohoku J Exp Med; 2020 Oct 17; 252(2):143-152. PubMed ID: 33028759
    [Abstract] [Full Text] [Related]

  • 18. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
    Al-Zakwani I, Zubaid M, Alsheikh-Ali AA, Almahmeed W, Rashed W.
    Cardiovasc Ther; 2018 Dec 17; 36(6):e12463. PubMed ID: 30079461
    [Abstract] [Full Text] [Related]

  • 19. Impact of Optimal Medical Therapy at Discharge on One-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China.
    He X, Wang Y, Cong H, Lu C, Wu J.
    Clin Ther; 2019 Mar 17; 41(3):456-465.e2. PubMed ID: 30770126
    [Abstract] [Full Text] [Related]

  • 20. Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention.
    Mohammed S, Arabi A, El-Menyar A, Abdulkarim S, AlJundi A, Alqahtani A, Arafa S, Al Suwaidi J.
    Curr Vasc Pharmacol; 2016 Mar 17; 14(4):388-93. PubMed ID: 26517700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.